IOVA Stock New: Contact Robbins LLP for Information About the Securities Fraud Class Action Against Iovance Biotherapeutics, Inc. and to Learn How to Be Lead Plaintiff for the Class

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Company Performance - Iovance Biotherapeutics reported a total product revenue of $49.3 million for Q1 2025, a significant decline from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [3]. - The updated revenue forecast reflects challenges with the launch dynamics of Amtagvi and the growth trajectories of Authorized Treatment Centers (ATCs) [3]. Allegations and Issues - The lawsuit claims that Iovance failed to disclose several critical issues, including: 1. New ATCs faced longer timelines to begin treating patients with Amtagvi [2]. 2. Ineffectiveness of the sales team and ATCs in patient identification and selection, leading to higher patient drop-offs [2]. 3. These dynamics resulted in higher costs and lower revenue due to ATCs not keeping pace with manufactured products [2]. 4. Positive statements made by the company regarding its business and prospects were materially misleading [2]. Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].